Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of TAK-360 in central disorders of hypersomnolence
CTR20262189Phase 2Active
- Sponsor
- Takeda
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TAK-360 in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), hypersomnolence disorder, sponsored by Takeda. Started Aug 2026; status: active.
02
Drugs
TAK-360
03
Conditions
narcolepsy type 1 (NT1)narcolepsy type 2 (NT2)hypersomnolence disorder
Beyond the preview
Go deeper on CTR20262189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262189.